Tags

Type your tag names separated by a space and hit enter

Aripiprazole in children and adolescents: clinical experience.
J Child Neurol. 2005 Jul; 20(7):603-10.JC

Abstract

Despite few supportive data, aripiprazole was being administered to children and adolescents for management of mood instability, aggression, and psychosis. Using a retrospective review (n = 11) and prospective recruitment (n = 6), 17 children and adolescents received aripiprazole 5 to 20 mg/day. Only 4 of 16 bipolar and autistic subjects (25%) demonstrated reduced aggression without adverse events, and the symptoms of 2 of 4 psychotic subjects improved. Coadministration of sedative medications (particularly guanfacine or clonidine) and weight < 58 kg increased the risk of adverse events, such as increased lability and aggression. All three children < 8.6 years old, all four children < 34 kg, and all five children receiving alpha2-agonists developed adverse events prior to clinical efficacy. Age > 11 years, weight > 58 kg, and absence of sedative medications were associated with a 56% (five of nine) success rate. Until larger, prospective studies are completed, caution is advised when considering aripiprazole for smaller children and children receiving sedative medications.

Authors+Show Affiliations

Children's Specialized Hospital, Toms River, NJ 08755, USA. trugino@childrens-specialized.orgNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16159529

Citation

Rugino, Thomas A., and Yvette M. Janvier. "Aripiprazole in Children and Adolescents: Clinical Experience." Journal of Child Neurology, vol. 20, no. 7, 2005, pp. 603-10.
Rugino TA, Janvier YM. Aripiprazole in children and adolescents: clinical experience. J Child Neurol. 2005;20(7):603-10.
Rugino, T. A., & Janvier, Y. M. (2005). Aripiprazole in children and adolescents: clinical experience. Journal of Child Neurology, 20(7), 603-10.
Rugino TA, Janvier YM. Aripiprazole in Children and Adolescents: Clinical Experience. J Child Neurol. 2005;20(7):603-10. PubMed PMID: 16159529.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Aripiprazole in children and adolescents: clinical experience. AU - Rugino,Thomas A, AU - Janvier,Yvette M, PY - 2005/9/15/pubmed PY - 2005/10/21/medline PY - 2005/9/15/entrez SP - 603 EP - 10 JF - Journal of child neurology JO - J. Child Neurol. VL - 20 IS - 7 N2 - Despite few supportive data, aripiprazole was being administered to children and adolescents for management of mood instability, aggression, and psychosis. Using a retrospective review (n = 11) and prospective recruitment (n = 6), 17 children and adolescents received aripiprazole 5 to 20 mg/day. Only 4 of 16 bipolar and autistic subjects (25%) demonstrated reduced aggression without adverse events, and the symptoms of 2 of 4 psychotic subjects improved. Coadministration of sedative medications (particularly guanfacine or clonidine) and weight < 58 kg increased the risk of adverse events, such as increased lability and aggression. All three children < 8.6 years old, all four children < 34 kg, and all five children receiving alpha2-agonists developed adverse events prior to clinical efficacy. Age > 11 years, weight > 58 kg, and absence of sedative medications were associated with a 56% (five of nine) success rate. Until larger, prospective studies are completed, caution is advised when considering aripiprazole for smaller children and children receiving sedative medications. SN - 0883-0738 UR - https://www.unboundmedicine.com/medline/citation/16159529/Aripiprazole_in_children_and_adolescents:_clinical_experience_ L2 - http://journals.sagepub.com/doi/full/10.1177/08830738050200071301?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -